Petros Pharmaceuticals, Inc. (PTPI)
OTCMKTS · Delayed Price · Currency is USD
0.0324
+0.0022 (7.32%)
At close: Aug 1, 2025
HashiCorp Revenue
Petros Pharmaceuticals had revenue of $5.11M in the twelve months ending March 31, 2025, up 54.70% year-over-year. In the year 2024, Petros Pharmaceuticals had annual revenue of $5.11M, down -12.20%.
Revenue
5.11M
Revenue Growth
+54.70%
P/S Ratio
0.27
Revenue / Employee
284.00K
Employees
18
Market Cap
1.37M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.11M | -710.35K | -12.20% |
Dec 31, 2023 | 5.82M | -169.67K | -2.83% |
Dec 31, 2022 | 5.99M | -1.82M | -23.29% |
Dec 31, 2021 | 7.81M | -1.75M | -18.29% |
Dec 31, 2020 | 9.56M | -6.02M | -38.63% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Petros Pharmaceuticals News
- 5 weeks ago - Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position - Accesswire
- 2 months ago - Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets - Accesswire
- 2 months ago - Petros Pharmaceuticals partners with Innolitics to accelerate SaaS platform development - Seeking Alpha
- 2 months ago - Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer - Accesswire
- 3 months ago - Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform - Accesswire
- 3 months ago - Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches - Accesswire
- 3 months ago - Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms - Accesswire
- 4 months ago - Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications - Accesswire